Vyleesi (Bremelanotide) for Hypoactive Sexual Desire Disorder
Indication
Vyleesi is FDA-approved specifically for treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. 1, 2, 3 This represents one of only two FDA-approved medications for this indication, characterized by persistent lack of motivation for sexual activity that causes significant distress. 2, 4
Dosing Regimen
- Administer 1.75 mg subcutaneously approximately 45 minutes prior to anticipated sexual activity 4, 5
- Maximum of 1 dose per 24 hours 4
- Maximum of 8 doses per month 4
- Discontinue after 8 weeks if no clinical benefit is observed 4
- The medication can be used as needed rather than requiring daily administration 4
Contraindications and Precautions
- Use with caution in patients at risk for cardiovascular disease 3
- Blood pressure must be well-controlled before and during treatment 3
- Small but statistically significant transient blood pressure increases occur during treatment 3
- Avoid use with naltrexone and indomethacin due to clinically significant drug interactions that lower plasma concentrations of these medications 3
- Most other drug-drug interactions are not clinically significant, including no significant interaction with alcohol 4
Side Effects
The adverse effect profile is generally mild to moderate but notable: 3, 4, 5
- Nausea: 40% (most common, versus 1.3% placebo) - this is the most frequent reason for discontinuation 3, 5
- Facial flushing: 20.3% (versus 1.3% placebo) 3, 5
- Headache: 11.3% (versus 1.9% placebo) 3, 5
- Injection site reactions: 5.4% (versus 0.5% placebo) 3
- Focal hyperpigmentation: rare when dosed per label recommendations, but occurred in >33% with consecutive daily dosing 3
- No deaths reported in clinical trials involving 3,500 subjects 3
- Serious adverse events were rare 3
Monitoring Requirements
- Monitor blood pressure before initiating therapy and periodically during treatment 3
- Assess clinical benefit at 8 weeks - discontinue if no improvement 4
- Monitor for hyperpigmentation, particularly if dosing frequency exceeds recommendations 3
- Evaluate for cardiovascular risk factors before prescribing 3
Efficacy Considerations
The clinical benefit appears modest despite statistical significance in trials. 1, 2, 4 In the two pivotal phase 3 trials (RECONNECT studies):
- Statistically significant increases in sexual desire scores (integrated studies: 0.35 increase, P<.001) 5
- Statistically significant reductions in distress related to low sexual desire (integrated studies: -0.33 reduction, P<.001) 5
- However, the overall clinical benefit is considered modest when interpreting these validated questionnaire changes 1, 4
- Results should be interpreted considering the significant placebo effect in female sexual dysfunction trials 1
Alternative Treatments
For premenopausal women with HSDD: 6, 2
- Flibanserin: The other FDA-approved medication for HSDD, taken daily (not as-needed), with side effects including dizziness, somnolence, nausea, and fatigue 6
- Off-label options: Bupropion and buspirone may be considered, though not FDA-approved for this indication 2
- Non-pharmacologic interventions: Psychotherapy, lifestyle modifications, and integrative therapies (yoga, meditation) should be incorporated as part of a multimodal approach 6, 2
- Testosterone: May be discussed as an option for low libido, though not FDA-approved for female HSDD 6
Clinical Context
Bremelanotide works as a melanocortin receptor agonist, hypothesized to trigger excitatory brain pathways that enhance sexual desire. 1 The medication was studied in trials lasting up to 18 months, with 1,247 subjects in the integrated safety population of phase 3 studies. 3, 5 Notably, 70% of bremelanotide-treated patients proceeded to open-label extension phases versus 87% on placebo, suggesting some discontinuation related to tolerability. 3